Gyre Therapeutics (FRA:L9S) Treasury Stock: €0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:L9S Gyre Therapeutics Inc FRA:L9S
39 GF Score
Price €5.75
GF Value €7.95
! 3 Warning Signs
View Full Analysis

What is Gyre Therapeutics Treasury Stock?

Gyre Therapeutics FRA:L9S -0.86% 39 Treasury Stock is €0.0 Mil as of Jun. 2026. GuruFocus rates FRA:L9S with a GF Score™ of 39/100 and a GF Value™ of €7.95. The stock has 3 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Gyre Therapeutics's treasury stock for the quarter that ended in Jun. 2026 was €0.0 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Gyre Therapeutics Treasury Stock Historical Data

* Premium members only.

The historical data trend for Gyre Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gyre Therapeutics Treasury Stock Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Treasury Stock
0.00 0.00 0.00 0.00 0.00

Gyre Therapeutics Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:L9S
39GF Score
Gyre Therapeutics Inc FRA:L9S
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gyre Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of €0.0 Mil mean?
Gyre Therapeutics (FRA:L9S) has a Treasury Stock of €0.0 Mil as of Jun. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Gyre Therapeutics and its competitors.
Is Gyre Therapeutics' Treasury Stock too high?
Gyre Therapeutics' current Treasury Stock is €0.0 Mil. Overall, Gyre Therapeutics has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Treasury Stock compare to OCS and RIGL?
Gyre Therapeutics' Treasury Stock of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Gyre Therapeutics and its competitors. Gyre Therapeutics's current Treasury Stock is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Gyre Therapeutics (FRA:L9S) has a current Treasury Stock of €0.0 Mil. The stock's GF Value™ is €7.95, compared to a current price of €5.75 — trading 27.7% below its estimated fair value. The current Treasury Stock is €0.0 Mil. Gyre Therapeutics' overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Gyre Therapeutics (FRA:L9S), the current Treasury Stock is €0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gyre Therapeutics (FRA:L9S) Overvalued in 2026?

Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued. The current stock price of €5.75 is trading 27.7% below its estimated GF Value™ of €7.95.

Key valuation signals for FRA:L9S:

  • Treasury Stock: €0.0 Mil
  • GF Value™: €7.95 vs. price of €5.75 (27.7% below fair value)
  • GF Score™: 39/100 with 3 warning signs

No single metric tells the full story. See the FRA:L9S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gyre Therapeutics Business Description

Other Exchanges GYRE:USA
Address 12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score

Get the complete analysis for FRA:L9S

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.75
Price
€7.95
GF Value